Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
Question
Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
Direct answer
Up to $795 million in milestone and licensing payments provides non-dilutive capital to fund pipeline clinical trials and extends Biohaven's operational cash runway. — bullish pressure on BHVN via non-dilutive licensing capital and pipeline milestone monetization.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-28
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim”, revision 1, evidence through 2026-08-28. https://marketontology.com/catalysts/2026-08-28/biohaven-secures-795m-licensing-pact-with-sk-biopharmaceuticals-for-opakalim-d99a68
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| BHVN | ▲Bull | 1–4 weeks | non-dilutive licensing capital and pipeline milestone monetization | 60 |
Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
Up to $795 million in milestone and licensing payments provides non-dilutive capital to fund pipeline clinical trials and extends Biohaven's operational cash runway. — bullish pressure on BHVN via non-dilutive licensing capital and pipeline milestone monetization.
Biohaven secured an exclusive licensing deal with SK Biopharmaceuticals worth up to $795M for its Kv7 platform.
- SourceBiohaven secured an exclusive licensing deal with SK Biopharmaceuticals worth up to $795M for its Kv7 platform.
- TransmissionUp to $795 million in milestone and licensing payments provides non-dilutive capital to fund pipeline clinical trials and extends Biohaven's operational cash runway.
- SummaryBiohaven signed a global collaboration agreement with SK Biopharmaceuticals valued up to $795 million. The deal grants exclusive rights to the Kv7 ion channel platform and lead drug opakalim. The transaction provides non-dilutive funding for central nervous system clinical programs.
- BHVNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- BHVN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- BHVN price vs. pre-event level
- BHVN volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Why Biohaven Stock Was Rocking the Market This Week · Polygon News · 2026-08-28
Related catalysts
- 2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for OpakalimBHVN
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
- 2026-08-28Biohaven partners with SK Biopharmaceuticals in $795M licensing dealBHVN
- 2026-08-28Biohaven partners with SK Biopharmaceuticals in $795M licensing dealBHVN
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.